融捷健康(300247) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 reached ¥251,599,497.82, representing a 42.68% increase compared to ¥176,333,541.57 in the same period last year[5] - Net profit attributable to shareholders was ¥30,984,169.91, up 48.78% from ¥20,825,834.91 year-on-year[5] - The net profit after deducting non-recurring gains and losses was ¥28,178,773.25, reflecting a 39.30% increase from ¥20,229,366.62 in the previous year[5] - Basic earnings per share rose to ¥0.0385, a 48.65% increase from ¥0.0259 year-on-year[5] - Operating income increased by ¥75,266,000, primarily due to higher sales revenue during the reporting period[12] - Operating profit for the current period was ¥55,832,485.11, up 51.8% from ¥36,780,586.93 in the previous period[24] - Total comprehensive income for the current period was ¥42,520,102.11, compared to ¥25,504,271.67 in the previous period, indicating a growth of 66.7%[25] Cash Flow and Assets - The net cash flow from operating activities was ¥69,773,882.69, an increase of 30.33% compared to ¥53,537,093.95 in the same period last year[5] - Cash inflow from operating activities increased by ¥79,617,300, a 42.16% rise, attributed to increased sales collections and recovery of prior receivables[14] - The company's cash and cash equivalents increased to ¥253,073,511.75 from ¥180,323,534.41, representing a growth of approximately 40.4%[21] - Cash and cash equivalents at the end of the period totaled ¥253,073,511.75, up from ¥223,882,753.18 in the previous period[28] - Total current assets amounted to ¥979,800,735.43, up from ¥947,370,678.98, indicating an increase of about 3.5%[21] - The total assets of the company reached ¥1,330,610,375.64, compared to ¥1,303,178,909.04 at the beginning of the period, reflecting a growth of approximately 2.1%[23] Shareholder Information - The total number of common shareholders at the end of the reporting period is 33,778[18] - The largest shareholder, Rongjie Investment Holdings, holds 14.54% of the shares, totaling 116,912,302 shares[18] - The company has no preferred shareholders as of the reporting period[19] Liabilities and Equity - The total liabilities decreased to ¥146,266,436.46 from ¥161,355,071.96, showing a reduction of about 9.3%[22] - The company's total equity increased to ¥1,184,343,939.18 from ¥1,141,823,837.08, which is an increase of approximately 3.7%[23] - Shareholders' equity attributable to the company was ¥1,096,335,652.91, up 2.88% from ¥1,065,690,539.17 at the end of the previous year[5] Other Financial Metrics - The company reported a decrease in other payables by ¥11,314,600, a 55.57% decline, mainly due to payments of previously accrued expenses[17] - The accounts receivable decreased to ¥66,917,173.84 from ¥72,624,486.81, a decline of about 7.5%[21] - Research and development expenses increased to ¥2,904,875.58, compared to ¥2,369,330.52 in the previous period, reflecting a growth of 22.5%[24] - The total operating costs for the current period were ¥198,022,819.87, up 36.6% from ¥144,828,814.76 in the previous period[24] - The company reported a net cash inflow from investment activities of ¥5,894,521.34, a decrease from ¥53,739,934.53 in the previous period[28] - The company reported a net loss of ¥-1,122,242,538.62, slightly improved from ¥-1,153,226,708.53 in the previous period[23]